Ravelcare's Q2 profit surged 97% sequentially, but a large jump in other income accounted for much of the gain, raising questions about core earnings sustainability.
Ravelcare's Q2 FY27 profit nearly doubled from the previous quarter, yet a significant portion stemmed from non-operational income. The company's core revenue growth was steady, while institutional investors continued to reduce their stake.
For Ravelcare, a personal care brand betting on new launches, the September quarter delivered a headline profit surge. Yet the numbers reveal a more nuanced story where a one-time income boost played a starring role.
The company's profit after tax nearly doubled to ₹3.84 crore from the March quarter, on a 20.6% sequential rise in revenue to ₹15.15 crore. Year-on-year, profit grew a solid 20% while revenue was up 5.2%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Revenue (₹ Cr) | 15.15YoY +5.2% | 14.40 |
| Profit (₹ Cr) | 3.84YoY +20% | 3.20 |
| Net Profit Margin | 25.3%YoY +14% | 22.2% |
The quarter's standout figure was other income, which surged to ₹0.72 crore from just ₹0.04 crore in the previous quarter. According to MarketsMojo, this accounted for a significant portion of the profit before tax of ₹5.17 crore. This non-operational gain, not detailed in filings, flattered the bottom-line growth.
Stripping that out, the underlying operating performance still showed improvement. Gross margin expanded 350 basis points year-on-year to 79.9%, notes Alfafinder. The company also cut product returns by 60% and raised average order value by 9% through website upgrades.
Management is upbeat, calling it a “solid first half” and betting on new products. A PRO range for marketplaces is live, and a personalised skincare line is slated for a December 2026 launch, with international expansion planned “soon”.
Live Chart
· RAVEL
(BSE)
ISIN: INE0W4D01018
Yet institutional investors have been pulling back. Data from Screener.in shows their combined stake fell from 11.68% in December 2025 to 5.8% by September 2026. This selling suggests some doubt about the sustainability of current margins or the execution of new launches.
Key Points
Ravelcare's quarter presents a split screen: strong operational discipline against a profit figure boosted by a one-off. The core business is healthier, with better margins and a new distribution channel gaining traction.
The path forward hinges on converting its product pipeline into consistent, high-margin sales without similar income surprises. The declining institutional interest adds a note of caution, making the coming quarters' pure operating performance critical for investor confidence.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.